DrugPatentWatch Database Preview
Patent: 9,920,311
Summary for Patent: 9,920,311
| Title: | PEGylated L-asparaginase |
| Abstract: | Disclosed is a conjugate of a protein having substantial L-asparagine aminohydrolase activity and polyethylene glycol. In particular, the polyethylene glycol has a molecular weight less than or equal to about 5000 Da and the protein is an L-asparaginase from Erwinia. The conjugate of the invention has shown superior properties such as maintenance of a high level of in vitro activity and an unexpected increase in half-life in vivo. Also disclosed are methods of producing the conjugate and use of the conjugate in therapy. In particular, a method is disclosed for use of the conjugate in the treatment of cancer, particularly Acute Lymphoblastic Leukemia (ALL). More specifically, a method is disclosed for use of the conjugate as a second line therapy for patients who have developed hypersensitivity or have had a disease relapse after treatment with other L-asparaginase preparations. |
| Inventor(s): | Abribat; Thierry (Sainte Foy les Lyon, FR) |
| Assignee: | Jazz Pharmaceuticals II SAS (Lyons, FR) |
| Application Number: | 14/819,305 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,920,311
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck | ELSPAR | asparaginase | VIAL | 101063 | 001 | 1978-01-10 | Start Trial | Jazz Pharmaceuticals II SAS (Lyons, FR) | 2030-03-30 | RX | search | |
| Jazz Pharms Inc | ERWINAZE | asparaginase erwinia chrysanthemi | INJECTABLE; INJECTION | 125359 | 001 | 2011-11-18 | Start Trial | Jazz Pharmaceuticals II SAS (Lyons, FR) | 2030-03-30 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
